

Attorney Docket No.: RTS-0245
Inventors: Monia and Cowser
Serial No.: 09/920,677
Filing Date: August 1, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

A' 1. (currently amended): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding p70 S6 kinase (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of p70 S6 kinase.

2. (original): The compound of claim 1 which is an antisense oligonucleotide.

Claims 3-4 (canceled)

5. (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

6. (original): The compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

7. (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

8. (original): The compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Attorney Docket No.: **RTS-0245**
Inventors: **Monia and Cowser**
Serial No.: **09/920,677**
Filing Date: **August 1, 2001**
Page 3

10. (original): The compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

A²
12. (currently amended): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding p70 S6 kinase (SEQ ID NO: 3).

13. (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

14. (original): The composition of claim 13 further comprising a colloidal dispersion system.

15. (original): The composition of claim 13 wherein the compound is an antisense oligonucleotide.

16. (original): A method of inhibiting the expression of p70 S6 kinase in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of p70 S6 kinase is inhibited.

17. (original): A method of treating an animal having a disease or condition associated with p70 S6 kinase comprising administering to said animal a therapeutically or prophylactically

Attorney Docket No.: RTS-0245
Inventors: Monia and Cowser
Serial No.: 09/920,677
Filing Date: August 1, 2001
Page 4

effective amount of the compound of claim 1 so that expression of p70 S6 kinase is inhibited.

18. (original): The method of claim 17 wherein the disease or condition is a hyperproliferative disorder.

19. (original): The method of claim 18 wherein the hyperproliferative disorder is cancer.

20. (original): The method of claim 16 wherein the disease or condition is a metabolic disorder.